stockrowSeres Therapeutics, Inc.
MCRB Healthcare Biotechnology
Seres Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $789,000.00, down 99.4% from fiscal 2023.
- Revenue
- +69.0%
- EPS
- −273.6%
- Free cash flow
- −576.7%
Quarter to September 2026, against a year earlier
Follow MCRB
Alert me
Seres Therapeutics, Inc. (MCRB) EV/Sales
As of 6 November 2026, Seres Therapeutics, Inc. (MCRB) trades at a EV/Sales of 49.2×. Over the past ten years it has ranged from 0.0× (December 2016) to 150× (April 2023); the current reading is higher than 80% of that period. That is above the Biotechnology industry median of 9.0× and above the Healthcare sector median of 3.6×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 128× | 10,509.53% |
| FY2023 | 1.2× | (98.10%) |
| FY2022 | 63.5× | 1,749.61% |
| FY2021 | 3.4× | (93.39%) |
| FY2020 | 52.0× | 1,331.19% |
| FY2019 | 3.6× | (2.37%) |
| FY2018 | 3.7× | (58.23%) |
| FY2017 | 8.9× | (10.45%) |
| FY2016 | 9.9× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Sep 2026 | 55.7× | (35.82%) |
| Jun 2026 | 86.8× | (16.24%) |
| Mar 2026 | 104× | (19.02%) |
| Dec 2025 | 128× | 7,206.58% |
| 33 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| ATOS Atossa Therapeutics, Inc. compare | −174× |
| FLNA Cassava Sciences, Inc. compare | n/m |
| IMMP Prima BioMed Ltd compare | n/m |
| BSEM BioStem Technologies, Inc. compare | 0.4× |
| CRVO CervoMed Inc. compare | 0.6× |
| EVAX Evaxion A/S - Sponsored ADR compare | 1.4× |
| COCP Cocrystal Pharma, Inc. compare | 9.0× |
| IGC IGC Pharma, Inc. compare | 19.3× |
| MCRB Seres Therapeutics, Inc. | 49.2× |
| Biotechnology industry median | 9.0× |
| Healthcare sector median | 3.6× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)